Niederberger Verena, Valenta Rudolf
Department of Otorhinolaryngology, Vienna General Hospital, Medical University of Vienna, Ebene 8J, Waehringer Guertel 18-20, Vienna A-1090, Austria.
Immunol Allergy Clin North Am. 2004 Nov;24(4):727-38. doi: 10.1016/j.iac.2004.06.009.
For more than 90 years, allergen-specific immunotherapy, the only causative allergy treatment, has remained basically unchanged. The development of molecular biology techniques has led to the preparation of individual recombinant allergens from the most important allergen sources. Recombinant allergens can be used to determine the individual sensitization profile of allergic patients and have allowed the development of novel therapeutic tools. This article summarizes data on genetically modified recombinant allergen derivatives with reduced allergenic activity, which may be used to improve the safety and efficacy of specific immunotherapy.
九十多年来,变应原特异性免疫疗法作为唯一的过敏性疾病病因治疗方法,基本没有变化。分子生物学技术的发展使得从最重要的变应原来源制备单个重组变应原成为可能。重组变应原可用于确定过敏性患者的个体致敏情况,并推动了新型治疗工具的开发。本文总结了关于变应原活性降低的转基因重组变应原衍生物的数据,这些衍生物可用于提高特异性免疫疗法的安全性和有效性。